Cite
Liang H, Wang Q, Wang D, et al. Corrigendum to "RGFP966, a histone deacetylase 3 inhibitor, promotes glioma stem cell differentiation by blocking TGF-β signaling via SMAD7" [Biochem. Pharmacol. 180 (2020) 114118]. Biochem Pharmacol. 2020;182:114223doi: 10.1016/j.bcp.2020.114223.
Liang, H., Wang, Q., Wang, D., Zheng, H., Kalvakolanu, D. V., Lu, H., Wen, N., Chen, X., Xu, L., Ren, J., Guo, B., & Zhang, L. (2020). Corrigendum to "RGFP966, a histone deacetylase 3 inhibitor, promotes glioma stem cell differentiation by blocking TGF-β signaling via SMAD7" [Biochem. Pharmacol. 180 (2020) 114118]. Biochemical pharmacology, 182114223. https://doi.org/10.1016/j.bcp.2020.114223
Liang, Hang, et al. "Corrigendum to "RGFP966, a histone deacetylase 3 inhibitor, promotes glioma stem cell differentiation by blocking TGF-β signaling via SMAD7" [Biochem. Pharmacol. 180 (2020) 114118]." Biochemical pharmacology vol. 182 (2020): 114223. doi: https://doi.org/10.1016/j.bcp.2020.114223
Liang H, Wang Q, Wang D, Zheng H, Kalvakolanu DV, Lu H, Wen N, Chen X, Xu L, Ren J, Guo B, Zhang L. Corrigendum to "RGFP966, a histone deacetylase 3 inhibitor, promotes glioma stem cell differentiation by blocking TGF-β signaling via SMAD7" [Biochem. Pharmacol. 180 (2020) 114118]. Biochem Pharmacol. 2020 Dec;182:114223. doi: 10.1016/j.bcp.2020.114223. Epub 2020 Oct 08. PMID: 33039815.
Copy
Download .nbib